We develop advanced genomic technologies that bridge experimental and clinical genomics through innovative sequencing approaches. Our platforms extend beyond research laboratories, reaching real-world settings such hospitals, farms, and environmental monitoring, expanding accessibility and translational impact.
A central focus is single-molecule transcript profiling using Nanopore technology with full-length and direct RNA sequencing, applied on human research and clinical samples. We combine experimental innovation and advanced computational tools to investigate RNA molecules at unprecedented resolution.
This approach enables us to explore regulatory layers that were previously overlooked due to technological limitations or incomplete knowledge. These include RNA isoforms, RNA modifications, their influence on RNA fate and function, and the contribution of transposable element transcripts in bulk and single-cell RNA sequencing datasets.

We investigate the roles of non-coding RNAs (ncRNAs) in neurological disorders and cancer, exploring their impact on physiology, neurodegeneration, inflammation, and adaptive behaviors. Our research includes studies on the role of transposable element–derived transcripts and small ncRNAs, such as microRNAs and piRNAs, in neurodisease, neuro-inflammation, and stem cell fate.
In cancer models, we use CRISPR-based platforms to identify genetic and RNA-based dependencies, extending functional interrogation to non-coding RNAs, and complex disease settings. These include tumor heterogeneity and microenvironmental interactions, studied through in vivo models and 3D cancer organoids, with particular attention to the role of RNA metabolism in tumor progression. We also develop and validate microRNA-based therapeutic approaches to restore tumor-suppressive RNA networks in relevant vivo models.
​ On the therapeutic side, we develop RNA-based strategies employing circular RNAs, SINEUPs, multiSINEUPs and aptamers. These approaches aim at restoring gene expression in neurodegenerative and complex diseases or exploiting synthetic lethality mechanisms in cancer.

Our research integrates computational modeling, advanced microscopy, and bioengineering to explore the structure, function, and therapeutic potential of RNA. Predictive models are developed to characterize RNA structures and interactions, identify binding sites, design aptamers, and assess the impact of genetic variants at scale.
Data-driven and machine learning approaches are tightly integrated with drug discovery efforts to identify and optimize RNA targets and compounds. We design small molecules and RNA-binding agents that selectively modulate RNA structures and interactions, advancing precise and personalized RNA-based therapeutics.
In parallel, next-generation imaging approaches are applied to investigate the dynamics and regulation of coding and non-coding RNAs at the subcellular level, combining super-resolution techniques, single-molecule tracking, and innovative labeling strategies.
Three-dimensional tissue models generated through bioprinting further enable high-throughput screening of RNA-based therapies, accelerating preclinical validation in physiologically relevant systems.